Cervical Cancer Clinical Trial Tracker — Monitor HPV-Driven Cancer Research

Why cervical cancer trial monitoring matters now

Cervical cancer has entered a new era of active clinical development. Pembrolizumab's approval in persistent/recurrent/metastatic disease and tisotumab vedotin's (TV) approval in second-line disease established two distinct treatment mechanisms. The current generation of trials is building on both, with 27 trials active on ClinicalTrials.gov and 14 currently recruiting.

Key areas driving new trial registrations:

• Pembrolizumab + TV combinations — testing synergy between checkpoint and TF-targeted ADC
• Next-generation ADCs targeting Tissue Factor (TF) and other cervical cancer antigens
• HPV-specific T cell receptor (TCR) therapies and cancer vaccines
• Neoadjuvant immunotherapy in locally advanced cervical cancer (a rapidly growing segment)
• HER2-targeted agents in HER2-amplified cervical cancer
• Novel VEGF combinations following bevacizumab's established role

What we monitor for cervical cancer

Configure your cervical cancer profile with the following options:

• Condition keywords: "cervical cancer", "cervical carcinoma", "HPV-positive cancer", "squamous cell carcinoma cervix", "adenocarcinoma cervix"
• Phase filter: Phase 1 for early pipeline, Phase 2/3 for registration-enabling and combination trials
• Sponsor filter: Industry-sponsored only, or all including NCI cooperative group trials
• Status filter: Recruiting only, or all active studies

The cervical cancer treatment landscape in 2026

Tisotumab vedotin follow-on combinations

Tisotumab vedotin's approval validated Tissue Factor as a clinically actionable target in cervical cancer. The innovaTV program is now exploring TV + pembrolizumab, TV + carboplatin, and TV + anti-VEGF combinations in both earlier lines and as maintenance. Competitor TF-targeted programs from other companies are also entering the clinical stage. Tracking these registrations maps the competitive landscape for TF-directed therapy.

HPV-targeted immunotherapy

Cervical cancer's HPV etiology makes it an ideal target for virus-directed immunotherapy. Multiple programs are developing TCR therapies targeting HPV E6 and E7 epitopes, therapeutic vaccines, and engineered T cell products. Several Phase 1/2 trials of HPV-specific cell therapy opened in 2025 and are recruiting at academic centers. This is one of the most distinctive features of cervical cancer clinical development compared to other solid tumors.

Neoadjuvant and organ-preservation approaches

Locally advanced cervical cancer has traditionally been treated with concurrent chemoradiation. A new generation of trials is testing neoadjuvant chemotherapy or immunotherapy before definitive CRT, with the goal of improving response rates and potentially enabling organ-preserving surgery. Phase 3 trial NCT07061977 is testing induction pembrolizumab + chemotherapy in this setting.

Global access and low-resource setting trials

Cervical cancer disproportionately affects women in low- and middle-income countries. Trials examining oral chemotherapy options, single-agent immunotherapy for resource-limited settings, and alternative RT schedules represent a unique component of the cervical cancer trial landscape that is often missed by conventional monitoring approaches.

Who uses cervical cancer trial monitoring

Gynecologic oncology BD teams

Companies developing assets in cervical cancer monitor competitor trial registrations to map the competitive landscape for TF-directed, HER2-directed, and immunotherapy approaches in this indication.

Radiation oncologists and gynecologic surgeons

Specialists treating locally advanced cervical cancer track neoadjuvant and concurrent therapy trial registrations to identify protocols potentially applicable to their patient populations and to understand emerging treatment algorithms.

Global health organizations and patient advocates

Organizations focused on cervical cancer elimination — WHO's 90-70-90 targets — monitor treatment and prevention trial activity to stay current on advances relevant to their advocacy and policy work.

Frequently asked questions

Does this cover HPV-positive oropharyngeal cancer as well?

Not by default, but you can add keywords like "HPV-positive head and neck cancer" or "oropharyngeal squamous cell carcinoma" to a separate profile. On the Starter plan ($49/month), you can have up to 5 profiles.

How current is the cervical cancer trial data?

Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest.

How is this different from ClinicalTrials.gov alerts?

ClinicalTrials.gov email alerts lack phase filtering, sponsor type filtering, and clean digest formatting. DataLookout provides filtered, labeled alerts — the intelligence layer on top of the raw registry data.